Business Expansion in Laboratory Automation
First written in FY2016. 9 of 31 entries say "Advanced", first in FY2018-Q1. Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1Decline in Revenue from Laboratory Automation EquipmentAnnual report
「In the interim period under review, sales were ¥214 million, down 15.0% year on year.」
Laboratory automation equipment recorded sales of ¥214 million, down 15.0% year on year, with the decline continuing. - FY2024Continued decline in laboratory automation equipment salesAnnual report
「In the fiscal year under review, sales were ¥344 million, down 48.6% year on year.」
Laboratory automation equipment for laboratories recorded sales of ¥344 million, down 48.6% year on year, continuing the sharp sales decline since FY2023. - FY2024-Q3Continued decline in laboratory automation equipment salesAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily nucleic acid automatic extraction systems, which we have marketed for some time. In the first 9 months of the fiscal year under review, sales were ¥319 million, down 48.0% year on year.」
Laboratory automation equipment recorded sales of ¥319 million, down 48.0% year on year, continuing the sales decline through FY2024-Q2. - FY2024-Q2Continued decline in laboratory automation equipment salesAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily nucleic acid automatic extraction systems, which we have marketed for some time. In the first 6 months of the fiscal year under review, sales were ¥252 million, down 50.8% year on year.」
Laboratory automation equipment recorded sales of ¥252 million, down 50.8% year on year, as the sharp sales decline through FY2024-Q1 continued. - FY2024-Q1Continued sharp decline in laboratory automation equipment salesAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the first 3 months of the fiscal year under review, sales were ¥86 million, down 73.5% year on year.」
Laboratory automation equipment recorded sales of ¥86 million, down 73.5% year on year, continuing the sharp sales decline seen since FY2023. - FY2023Sharp decline in laboratory automation equipment salesAnnual report
「This segment covers sales of various types of laboratory automation equipment for laboratories, primarily DNA/RNA (nucleic acid) automatic extraction systems, which we have marketed for some time. In the fiscal year under review, sales were ¥670 million, down 52.3% year on year.」
Laboratory automation equipment recorded sales of ¥670 million, down 52.3% year on year, with the decline widening further from the downward trend through the previous fiscal year. - FY2023-Q3Continued decline in laboratory automation equipment salesAnnual report
「This segment covers sales of various types of laboratory automation equipment for laboratories, primarily DNA/RNA (nucleic acid) automatic extraction systems, which we have marketed for some time. In the first 9 months of the fiscal year under review, sales were ¥614 million, down 37.0% year on year.」
Laboratory automation equipment recorded sales of ¥614 million, down 37.0% year on year, continuing the sales decline seen through the previous quarter. - FY2023-Q2Continued decline in laboratory automation equipment salesAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the first 6 months of the fiscal year under review, sales were ¥512 million, down 36.8% year on year.」
Laboratory automation equipment recorded sales of ¥512 million, down 36.8% year on year, with the decline in sales continuing. - FY2023-Q1Continued decline in laboratory automation equipment salesAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the first 3 months of the fiscal year under review, sales were ¥326 million, down 13.1% year on year.」
Laboratory automation equipment recorded sales of ¥326 million, down 13.1% year on year, continuing the decline from the previous fiscal year. - FY2022Continued decline in laboratory automation equipment salesAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the fiscal year under review, sales were ¥1,406 million, down 13.3% year on year.」
Laboratory automation equipment recorded another year of lower sales, at ¥1,406 million, down 13.3% year on year. - FY2022-Q3Correction-driven decline in laboratory automation equipment salesAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the first 9 months of the fiscal year under review, sales were ¥975 million, down 25.0% year on year. The decline in sales was attributable to a reaction to the sharp expansion in sales of DNA (nucleic acid) extraction systems to certain OEM customers in the previous fiscal year.」
Laboratory automation equipment recorded sales of ¥975 million, down 25.0% year on year, following a reaction to the sharp expansion in sales to certain OEM customers in the previous fiscal year. - FY2022-Q2Decline in Revenue from Laboratory Automation EquipmentAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the first 6 months of the fiscal year under review, sales were ¥811 million, down 8.7% year on year.」
Laboratory automation equipment recorded sales of ¥811 million, down 8.7% year on year, resulting in lower sales than in the same period of the previous year. - FY2022-Q1Decline in Revenue from Laboratory Automation EquipmentAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the first 3 months of the fiscal year under review, sales were ¥375 million, down 10.9% year on year.」
Laboratory automation equipment recorded sales of ¥375 million, down 10.9% year on year, turning to a sales decline. - FY2021Slight decline in laboratory automation equipment sales; OEM sales remain steadyAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the fiscal year under review, sales were ¥1,622 million, down 1.7% year on year. Sales were nearly unchanged from the previous fiscal year because sales of DNA automatic extraction systems supplied on an OEM basis to business partners worldwide remained steady.」
Laboratory automation equipment recorded sales of ¥1,622 million, down 1.7% year on year, while OEM supply of DNA automatic extraction systems to business partners worldwide was reported to be proceeding steadily. - FY2021-Q3AdvancedAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the first 9 months of the fiscal year under review, sales were ¥1,300 million, up 15.4% year on year. The increase in sales was attributable to steady sales of DNA automatic extraction systems supplied on an OEM basis to business partners worldwide.」
Laboratory automation equipment recorded sales of ¥1,300 million, up 15.4% year on year, as OEM supply of DNA automatic extraction systems to business partners worldwide remained steady. - FY2021-Q2AdvancedAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the first 6 months of the fiscal year under review, sales were ¥889 million, up 38.7% year on year. The increase in sales was attributable to steady sales of DNA automatic extraction systems sold directly by us and supplied on an OEM basis to business partners worldwide.」
Laboratory automation equipment recorded sales of ¥889 million, up 38.7% year on year, as direct sales and OEM supply to business partners worldwide remained steady. - FY2021-Q1AdvancedAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the first 3 months of the fiscal year under review, sales were ¥421 million, up 41.9% year on year. The increase in sales was attributable to steady sales of DNA automatic extraction systems supplied on an OEM basis to business partners worldwide.」
Laboratory automation equipment recorded sales of ¥421 million, up 41.9% year on year, as OEM sales of DNA automatic extraction systems to business partners worldwide remained steady. - FY2020AdvancedAnnual report
「Development of the new PreLEAD model, a simultaneous multi-sample nucleic acid extraction system, has been completed, and it has begun to be introduced in areas with demand for large-volume and high-throughput processing, broadening the applications of DNA extraction technology.」
Specific progress was reported, including completion of development of the new PreLEAD model and the start of its introduction in large-volume and high-throughput applications. - FY2020-Q3Slight sales growth from OEM salesAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the first 9 months of the fiscal year under review, sales were ¥1,127 million, up 1.1% year on year. The increase in sales was attributable to steady sales of DNA automatic extraction systems supplied on an OEM basis to business partners worldwide.」
Laboratory automation equipment recorded sales growth of 1.1% year on year as OEM sales of DNA automatic extraction systems remained steady. - FY2020-Q2Decline in Revenue from Laboratory Automation EquipmentAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the first 6 months of the fiscal year under review, sales were ¥641 million, down 12.8% year on year.」
Laboratory automation equipment recorded sales of ¥641 million, down 12.8% year on year, turning from sales growth in the same period of the previous year to a decline. - FY2020-Q1Decline in Revenue from Laboratory Automation EquipmentAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the first 3 months of the fiscal year under review, sales were ¥297 million, down 11.4% year on year.」
Laboratory automation equipment recorded sales of ¥297 million, down 11.4% year on year, resulting in lower sales. - FY2019AdvancedAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the fiscal year under review, sales were ¥1,610 million, up 38.8% year on year. Meanwhile, operating expenses were ¥1,435 million, up 42.6%, and operating income was ¥174 million, up 13.9%.」
Laboratory automation equipment exceeded the previous fiscal year's sales and operating income, with sales of ¥1,610 million and operating income of ¥174 million. - FY2019-Q3AdvancedAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the first 9 months of the fiscal year under review, sales were ¥1,115 million, up 31.1% year on year. Operating expenses were ¥905 million, up 25.6%, and operating income was ¥209 million, up 61.7%. The increase in sales and earnings was attributable to strong sales of DNA automatic extraction systems supplied on an OEM basis to business partners worldwide.」
Laboratory automation equipment recorded sales growth of 31.1% and operating income growth of 61.7% year on year, supported by strong OEM sales of DNA automatic extraction systems. - FY2019-Q2AdvancedAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the first 6 months of the fiscal year under review, sales were ¥735 million, up 14.7% year on year. Operating expenses were ¥566 million, up 5.4%, and operating income was ¥168 million, up 62.5%. The increase in sales and earnings was attributable to strong sales of DNA automatic extraction systems supplied on an OEM basis to business partners worldwide.」
Laboratory automation equipment recorded sales growth of 14.7% and operating income growth of 62.5% year on year, driven by strong OEM sales of DNA automatic extraction systems. - FY2019-Q1AdvancedAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the first quarter of the fiscal year under review, sales were ¥335 million, up 21.5% year on year. Operating expenses were ¥262 million, up 5.8%, and operating income was ¥72 million, up 160.6%.」
Laboratory automation equipment recorded sales growth of 21.5% and operating income growth of 160.6% year on year, resulting in higher sales and earnings. - FY2018Lower sales and operating income from laboratory automation equipmentAnnual report
「This segment covers sales of various types of laboratory automation equipment, primarily DNA automatic extraction systems, which we have marketed for some time. In the fiscal year under review, sales were ¥1,160 million, down 10.4% year on year. Meanwhile, operating expenses were ¥1,006 million, down 7.6%, and operating income was ¥153 million, down 25.1%.」
Laboratory automation equipment recorded lower sales and operating income than in the same period of the previous year, resulting in lower sales and earnings. - FY2018-Q3Lower revenue and lower profit despite strong direct sales and weak OEM salesAnnual report
「For the first 3 quarters of the fiscal year, cumulative net sales were ¥850 million, down 10.4% year on year. Operating expenses were ¥720 million, down 11.0%, while operating income was ¥129 million, down 7.0%. Net sales fluctuate somewhat from quarter to quarter depending on the operating and inventory conditions of OEM customers. In the first 3 quarters, direct sales were strong, but sales to OEM customers were weak, resulting in lower sales and operating income overall.」
Strong direct sales were offset by weak sales to OEM customers, resulting in lower net sales and operating income for laboratory automation equipment. - FY2018-Q2Lower revenue and higher profit due to weak OEM sales and strong direct salesAnnual report
「For the first 2 quarters of the fiscal year, cumulative net sales were ¥641 million, down 8.3% year on year. Operating expenses were ¥537 million, down 11.8%, while operating income was ¥103 million, up 14.9%.」
Laboratory automation equipment reported lower sales because sales to OEM customers were weak despite strong direct sales. Operating income increased as operating expenses declined. - FY2018-Q1AdvancedAnnual report
「For the first quarter of the fiscal year, cumulative net sales were ¥276 million, up 26.9% year on year. Operating expenses were ¥248 million, up 17.3%, while operating income was ¥27 million, up 365.0%. Net sales fluctuate somewhat from quarter to quarter depending on the operating and inventory conditions of OEM customers. In the first quarter, however, sales to U.S. OEM customers and direct sales were strong, resulting in higher sales and operating income year on year.」
Strong sales to U.S. OEM customers and direct sales led to a 26.9% year-on-year increase in net sales and a 365.0% increase in operating income for laboratory automation equipment. - FY2017RestatedAnnual report
「We will continue to focus on strengthening our products through performance improvements and cost reductions based on customer requirements. In recent years, demand has emerged for the automation of complex sample-preparation processes in a range of research fields, including epigenetics, which analyzes whether genes are functioning normally, and preparation for next-generation sequencers, which rapidly determine gene sequences. By meeting these needs, we intend to expand the applications of our automated DNA extraction systems.」
The policy of expanding the laboratory automation business through performance improvements, cost reductions and support for complex sample-preparation processes was reaffirmed. - FY2016First statedAnnual report
「We will continue to focus on strengthening our products through performance improvements and cost reductions based on customer requirements. In recent years, demand has emerged for the automation of complex sample-preparation processes in a range of research fields, including epigenetics, which analyzes whether genes are functioning normally, and preparation for next-generation sequencers, which rapidly determine gene sequences. By meeting these needs, we intend to expand the applications of our automated DNA extraction systems.」
Measures to expand the applications of the existing laboratory automation business through performance improvements, cost reductions and support for complex sample-preparation processes.